SCHEDULE: Vanguard Group Reports Zero Haemonetics Stake After Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Haemonetics Corp following an internal realignment that disaggregated reporting responsibilities.

Summary

• The Vanguard Group filed an Amendment No. 15 to Schedule 13G regarding its beneficial ownership in Haemonetics Corp.
• As of March 13, 2026, The Vanguard Group reports 0% beneficial ownership of Haemonetics Corp common stock.
• This change is due to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions now report beneficial ownership separately, in reliance on SEC Release No. 34-39538 (January 12, 1998).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities held by these disaggregated entities.
• The filing certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Haemonetics Corp.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update. It clarifies The Vanguard Group's reporting structure but provides no new information on Haemonetics Corp's performance or direct investment sentiment from Vanguard's perspective.

Positives

• The filing clarifies the reporting structure of The Vanguard Group, indicating adherence to SEC guidelines for disaggregated reporting.
• The certification confirms that the previous holdings (now disaggregated) were for ordinary course investment purposes, not for control influence.

Negatives

• The Vanguard Group, as the primary reporting entity, no longer holds a direct beneficial ownership stake in Haemonetics Corp, which might be interpreted by some as a reduction in direct institutional interest, although it is a structural change.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding Haemonetics Corp's future performance or The Vanguard Group's future investment intentions beyond the structural change in reporting.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• Securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this filing reflects a common practice among large asset managers like The Vanguard Group to periodically review and adjust their internal reporting structures to comply with regulatory guidance, such as SEC Release No. 34-39538. This realignment is an internal administrative change for Vanguard and does not inherently reflect a change in investment strategy towards Haemonetics Corp by Vanguard's underlying funds, which will now report separately.

Comparison to Industry Standards

• This filing is a standard regulatory update for a large institutional investor like The Vanguard Group, aligning its reporting practices with SEC guidelines for disaggregated beneficial ownership.
• Similar internal realignments and subsequent Schedule 13G/A filings are common among major asset managers such as BlackRock, State Street, and Fidelity, who manage vast portfolios through various subsidiaries and funds.
• The reporting of 0% beneficial ownership by the parent entity, while subsidiaries report separately, is a direct consequence of such structural changes, consistent with industry practice for large, diversified investment firms.

Corporate Governance

Stakeholder Impact

• Shareholders (Haemonetics Corp): No direct operational or financial impact. The change is administrative for a major institutional investor. Investors should be aware that Vanguard's overall exposure to Haemonetics Corp may still exist through its subsidiaries, just reported differently.
• The Vanguard Group (Internal): Streamlines reporting responsibilities by disaggregating beneficial ownership to specific subsidiaries/business divisions, aligning with SEC guidance.

Next Steps

• Future beneficial ownership filings for Haemonetics Corp by Vanguard's subsidiaries or business divisions will be reported separately.

Key Dates

Recommendation

This filing is purely administrative, detailing a change in The Vanguard Group's internal reporting structure for beneficial ownership. It does not provide any new information regarding Haemonetics Corp's financial performance, operational outlook, or The Vanguard Group's underlying investment strategy. Therefore, it offers no basis for a change in investment recommendation for Haemonetics Corp, warranting a 'hold' position based solely on this filing.

Keywords

Vanguard Group, Haemonetics Corp, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Investment Adviser, Corporate Governance, Realignment